These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24893685)

  • 1. Hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt: a retrospective case-control study.
    De Santis A; Iegri C; Kondili L; Riggio O; Salvatori FM; Catalano C; Di Martino M; Bassanelli C; Lupo M; Lucatelli P; Attili AF
    Dig Liver Dis; 2014 Aug; 46(8):726-30. PubMed ID: 24893685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the risk factors of hepatocellular carcinoma and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal hypertension.
    Wei J; Li H; Li C
    J Cancer Res Ther; 2018; 14(4):826-832. PubMed ID: 29970660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transjugular intrahepatic porto-systemic shunt is a risk factor for liver dysplasia but not hepatocellular carcinoma: a retrospective study of explanted livers.
    Borentain P; Garcia S; Gregoire E; Vidal V; Ananian P; Ressiot E; Hardwigsen J; Bartoli JM; Moulin G; Botta-Fridlund D; Le Treut YP; Gerolami R
    Dig Liver Dis; 2015 Jan; 47(1):57-61. PubMed ID: 25308609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.
    Qiu B; Zhao MF; Yue ZD; Zhao HW; Wang L; Fan ZH; He FL; Dai S; Yao JN; Liu FQ
    World J Gastroenterol; 2015 Nov; 21(43):12439-47. PubMed ID: 26604651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with cirrhosis and bare-stent TIPS may have increased risk of hepatocellular carcinoma.
    Bañares R; Núñez O; Escudero M; Fernández C; Vaquero J; Beceiro I; Echenagusía A; Clemente G; Santos L
    Hepatology; 2005 Mar; 41(3):566-71. PubMed ID: 15726654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension.
    Yao J; Zuo L; An G; Yue Z; Zhao H; Wang L; Liu F
    J Gastrointestin Liver Dis; 2015 Sep; 24(3):301-7. PubMed ID: 26405702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
    Berres ML; Lehmann J; Jansen C; Görtzen J; Meyer C; Thomas D; Zimmermann HW; Kroy D; Schumacher F; Strassburg CP; Sauerbruch T; Trautwein C; Wasmuth HE; Trebicka J
    Liver Int; 2016 Mar; 36(3):386-94. PubMed ID: 26212075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
    J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience.
    Lodato F; Berzigotti A; Lisotti A; Azzaroli F; Mosconi C; Giampalma E; Renzulli M; Cappelli A; Buonfiglioli F; Calvanese C; Zoli M; Golfieri R; Mazzella G
    Scand J Gastroenterol; 2012 Dec; 47(12):1494-500. PubMed ID: 22958120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and long-term evolution of TIPS in cirrhotic patients with portal thrombosis.
    Perarnau JM; Baju A; D'alteroche L; Viguier J; Ayoub J
    Eur J Gastroenterol Hepatol; 2010 Sep; 22(9):1093-8. PubMed ID: 20308910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percutaneous treatment of hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts.
    Tesdal IK; Wikström M; Flechtenmacher C; Filser T; Dueber C
    Cardiovasc Intervent Radiol; 2006; 29(5):778-84. PubMed ID: 16779690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Covered stents are better than uncovered stents for transjugular intrahepatic portosystemic shunts in cirrhotic patients with refractory ascites: a retrospective cohort study.
    Maleux G; Perez-Gutierrez NA; Evrard S; Mroue A; Le Moine O; Laleman W; Nevens F
    Acta Gastroenterol Belg; 2010; 73(3):336-41. PubMed ID: 21086935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma in Patients with Transjugular Intrahepatic Portosystemic Shunts.
    Park JK; Al-Tariq QZ; Zaw TM; Raman SS; Lu DS
    Cardiovasc Intervent Radiol; 2015 Oct; 38(5):1211-7. PubMed ID: 25670215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in patients with refractory ascites treated by transjugular intrahepatic porto-systemic shunt: From the liver to the kidney.
    Hamel B; Guillaud O; Roman S; Vallin M; Pilleul F; Valette PJ; Henry L; Guibal A; Mion F; Dumortier J
    Dig Liver Dis; 2014 Nov; 46(11):1001-7. PubMed ID: 25096966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trans-jugular intrahepatic portosystemic shunt in patients with hepatic cellular carcinoma: A preliminary study.
    Dong H; Zhang C; Li Z; Yang H; Wang Y; Liu J; Liu B; Mao S
    J Cancer Res Ther; 2021 Jul; 17(3):784-789. PubMed ID: 34269314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transjugular intrahepatic portosystemic shunt placement increases feasibility of colorectal surgery in cirrhotic patients with severe portal hypertension.
    Menahem B; Lubrano J; Desjouis A; Lepennec V; Lebreton G; Alves A
    Dig Liver Dis; 2015 Jan; 47(1):81-4. PubMed ID: 25445406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt.
    Rabie RN; Cazzaniga M; Salerno F; Wong F
    Am J Gastroenterol; 2009 Oct; 104(10):2458-66. PubMed ID: 19532126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prosthetic H-graft portacaval shunts vs transjugular intrahepatic portasystemic stent shunts: 18-year follow-up of a randomized trial.
    Rosemurgy AS; Frohman HA; Teta AF; Luberice K; Ross SB
    J Am Coll Surg; 2012 Apr; 214(4):445-53; discussion 453-5. PubMed ID: 22463885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Transjugular intrahepatic portosystemic shunt and combination with percutaneous transhepatic or transsplenic approach for the treatment of portal vein thrombosis with or without cavernomatous transformation].
    Han GH; Meng XJ; Yin ZX; Wang JH; He CY; Liang J; Guo XG; Liu J; Ding L; Wu KC; Fan DM
    Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(22):1549-52. PubMed ID: 19953883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of transjugular intrahepatic portosystemic shunt on glycometabolism in cirrhosis patients.
    Su AP; Cao SS; Le Tian B; Da Zhang Z; Hu WM; Zhang Y; Wang ZL; Babu SR; Hu T
    Clin Res Hepatol Gastroenterol; 2012 Feb; 36(1):53-9. PubMed ID: 22099870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.